Acyclic nucleoside phosphonates: a key class of antiviral drugs.
about
Peptides that bind the HIV-1 integrase and modulate its enzymatic activity--kinetic studies and mode of actionThe development of antiretroviral therapy and its impact on the HIV-1/AIDS pandemicHIV Genome-Wide Protein Associations: a Review of 30 Years of ResearchNew strategies against drug resistance to herpes simplex virusAn Odyssey in antiviral drug development-50 years at the Rega Institute: 1964-2014Prodrugs of phosphonates and phosphates: crossing the membrane barrierThe Octadecyloxyethyl Ester of (S)-9-[3-Hydroxy-2-(Phosphonomethoxy) Propyl]Adenine Is a Potent and Selective Inhibitor of Hepatitis C Virus Replication in Genotype 1A, 1B, and 2A RepliconsNucleoside diphosphate kinase and the activation of antiviral phosphonate analogs of nucleotides: binding mode and phosphorylation of tenofovir derivativesSolution Structure of a DNA Duplex Containing the Potent Anti-Poxvirus Agent CidofovirPhosphonoformic Acid Inhibits Viral Replication by Trapping the Closed Form of the DNA PolymeraseApproved Antiviral Drugs over the Past 50 YearsStructure of the Varicella Zoster Virus Thymidylate Synthase Establishes Functional and Structural Similarities as the Human Enzyme and Potentiates Itself as a Target of BrivudineDiscovery of an acyclic nucleoside phosphonate that inhibits Mycobacterium tuberculosis ThyX based on the binding mode of a 5-alkynyl substrate analogue.Gene induction for the treatment of methylmalonic aciduria.Emerging drugs for varicella-zoster virus infections.Potent inhibition of the C-P lyase nucleosidase PhnI by Immucillin-A triphosphate.Synthesis of a new family of acyclic nucleoside phosphonates, analogues of TPases transition states.Efficacy and safety of tenofovir disoproxil fumarate in patients with chronic hepatitis B.Poxvirus interleukin-4 expression overcomes inherent resistance and vaccine-induced immunity: pathogenesis, prophylaxis, and antiviral therapy.Enantiomerically pure phosphonated carbocyclic 2'-oxa-3'-azanucleosides: synthesis and biological evaluation.Antiproliferative property of hexadecyloxypropyl 9-[2-(phosphonomethoxy) ethyl] guanine (HDP-PMEG) for unwanted ocular proliferationNucleotide binding to human UMP-CMP kinase using fluorescent derivatives -- a screening based on affinity for the UMP-CMP binding site.Effect of phosphonated carbocyclic 2'-oxa-3'-aza-nucleoside on human T-cell leukemia virus type 1 infection in vitro.Polyomavirus BK infection in blood and marrow transplant recipients.Cidofovir selectivity is based on the different response of normal and cancer cells to DNA damage.New approaches in the management of chronic hepatitis B: role of tenofovir.Nucleoside transporter proteins as biomarkers of drug responsiveness and drug targets.Solution-phase parallel synthesis of acyclic nucleoside libraries of purine, pyrimidine, and triazole acetamides.Inhibition of HIV-1 by octadecyloxyethyl esters of (S)-[3-hydroxy-2-(phosphonomethoxy)propyl] nucleosides and evaluation of their mechanism of action.Current Antiviral Therapy of Chronic Hepatitis B: Efficacy and SafetyAntiviral activities of novel 5-phosphono-pent-2-en-1-yl nucleosides and their alkoxyalkyl phosphonoestersThe broad-spectrum anti-DNA virus agent cidofovir inhibits lung metastasis of virus-independent, FGF2-driven tumors.Synthesis and P2Y₂ receptor agonist activities of uridine 5'-phosphonate analogues.Transporter-targeted lipid prodrugs of cyclic cidofovir: a potential approach for the treatment of cytomegalovirus retinitis.New trends in nucleoside biotechnologyEvaluation of hexadecyloxypropyl-9-R-[2-(Phosphonomethoxy)propyl]- adenine, CMX157, as a potential treatment for human immunodeficiency virus type 1 and hepatitis B virus infections.Adenine: an important drug scaffold for the design of antiviral agentsA drug evaluation of 1% tenofovir gel and tenofovir disoproxil fumarate tablets for the prevention of HIV infectionDesign and profiling of GS-9148, a novel nucleotide analog active against nucleoside-resistant variants of human immunodeficiency virus type 1, and its orally bioavailable phosphonoamidate prodrug, GS-9131.Advances in the antiviral therapy of herpes virus infection in children.
P2860
Q24316120-F38D98D2-0D0D-4060-BD47-10121823BA8EQ24655011-5F97B842-2B3C-4598-9A2F-07BB5C3D5EFBQ26746070-574F75E2-13EC-404F-9B04-A3BCB54C34E7Q26749548-EEAF59B1-8AA2-47DF-94DE-F4A65BA964FAQ26771734-C1ED4A01-5249-4AD7-AA74-325BEB7968BAQ27005712-050B409B-EF6A-4931-9DD2-CF7CCD7094A2Q27488429-6EFECA04-7E6F-46B7-9556-F77A19CDB6A0Q27660045-63953A84-18FE-41FC-80DD-FB1DF9C17610Q27666791-37681EC6-E306-4A77-BA1A-EF70E657B7F6Q27667828-0B7496A2-B5FC-446F-85C7-29FD20D08758Q27755387-5BA0BACD-6B48-4B8F-975C-0BF7557C6D1FQ28551253-1EBF4378-4393-4B5A-AF57-CE3C63320335Q30654112-46823188-2F6A-4881-B3CB-3B84F714B46EQ30857770-37920DB1-B4DD-4235-8FDB-C755A2A70FA3Q34027426-374BF537-E63A-4FDF-A8D9-8048D8990A2EQ34038463-929085CE-5928-4FFE-B661-D9083160867FQ34204157-6235FF5F-2B3B-43A1-9878-386946BB03BFQ34409132-62C8ED9A-896C-49C7-AC1E-58BDDD309B34Q34432037-FD5205EE-E5DF-471B-9921-3347CAB22D38Q34438680-A8A710F7-9FE5-4907-83C7-3B31BD0A2B1BQ34628633-BD933016-E429-4704-B672-4B5EAE562277Q34645464-66BF7248-8594-4DD1-82A0-C11C482EC5F1Q34707606-54AC83DF-5147-48D1-ACB1-DA29F713DC48Q34732733-70585927-16A5-4951-9BC4-FC272824B99EQ34736407-0B871DE9-3B73-47B2-B5E4-B1D7F3EDDCAAQ35026531-ACDC29B5-36E6-45C9-9B8F-9209B6D4DC45Q35066350-F25F43B0-2BF2-485E-AFE7-18127E204DE5Q35189034-BB457988-3F2A-46B4-BE09-5B0D5CE31AA4Q35364463-741861A5-6CFF-4099-A18C-E0AD8D36891CQ35535861-049F3FC4-4558-47B2-8C87-7F8A90D540CCQ35636006-37F7F862-FD1E-471F-8288-0112620EB247Q35741522-C3C9FC28-E2E5-46C7-94D7-385A9B475501Q35830876-90AFF267-81EA-4DD8-A0E0-9E316F1FC90AQ35892584-4AE988D5-57F7-4A2D-BF58-34FA2508621AQ35944327-4970738B-D0E1-4F46-B6DA-79F1F9050184Q36095046-1013D4FF-5DEF-4A01-8AAE-EA43E551CCA1Q36238668-3CA6A0DA-9EE8-45EB-8AB1-86199A5CB501Q36286901-A32F6832-C986-44FD-8702-C7A2828CCFBFQ36425068-C00991A2-1618-4008-9F1E-B1248871183EQ36688958-C58C9102-C802-43D5-80DE-04A90DB44FF1
P2860
Acyclic nucleoside phosphonates: a key class of antiviral drugs.
description
2005 nî lūn-bûn
@nan
2005 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Acyclic nucleoside phosphonates: a key class of antiviral drugs.
@ast
Acyclic nucleoside phosphonates: a key class of antiviral drugs.
@en
Acyclic nucleoside phosphonates: a key class of antiviral drugs.
@nl
type
label
Acyclic nucleoside phosphonates: a key class of antiviral drugs.
@ast
Acyclic nucleoside phosphonates: a key class of antiviral drugs.
@en
Acyclic nucleoside phosphonates: a key class of antiviral drugs.
@nl
prefLabel
Acyclic nucleoside phosphonates: a key class of antiviral drugs.
@ast
Acyclic nucleoside phosphonates: a key class of antiviral drugs.
@en
Acyclic nucleoside phosphonates: a key class of antiviral drugs.
@nl
P2860
P356
P1476
Acyclic nucleoside phosphonates: a key class of antiviral drugs.
@en
P2860
P2888
P304
P356
10.1038/NRD1877
P577
2005-11-01T00:00:00Z